BCYC · Bicycle Therapeutics PLC · Executive Compensation

$3.86 +0.03 (+0.78%) At close · Sep 11

Market Cap

$270.17M

69.99M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Lee	Ph.D., MBA Chief Executive Officer	$516,950	$63,907	—	$3,370,651	$368,484	$56,305	$4,376,296
Lee Kalowski	Chief Financial Officer and President	$416,568	—	—	$1,826,955	$237,610	—	$2,481,133
Michael Skynner	Chief Operating Officer	$361,072	—	—	$1,192,094	$212,390	$52,572	$1,818,129

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Lee	Ph.D., MBA Chief Executive Officer	$385,549	$127,630	—	—	$267,904	$36,811	$817,894
Lee Kalowski	Chief Financial Officer and President	$349,520	$60,000	—	—	$110,536	—	$520,056

Executive changes

Person	Role	Change	Effective	Filed
Charles Swanton	Class II director of the Board of Directors	Resigned	2026-08-18	2026-08-20
Jennifer Perry	Chief Operating Officer	Appointed	2026-03-17	2026-03-17
Travis Thompson	Chief Financial Officer	Appointed	2026-01-29	2026-02-03
Hervé Hoppenot	Class I director	Appointed	2025-09-08	2025-09-08
Roger Dansey, M.D.	Class III director	Appointed	2025-09-08	2025-09-08
Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP	Director	Appointed	2025-08-12	2025-08-08
Fabrice André, M.D., Ph.D.	Clinical Advisory Board member	Appointed	—	2025-03-27
Eric Westin, M.D.	chief medical officer	Appointed	—	2025-03-27
Jim MacDonald-Clink	senior vice president, head of business development	Appointed	—	2025-03-27
Santiago Arroyo, M.D., Ph.D.	Chief Development Officer	Resigned	2025-03-24	2025-03-27
Richard Kender	Director	Retired	2025-06-17	2025-03-27
Felix J. Baker, Ph.D.	Chairman of the Board of Directors	Appointed	—	2025-03-27
Pierre Legault	Director	Retired	2025-06-17	2025-03-27
Alessandro Riva, M.D.	Class III director (member of the Board and the Scientific Committee)	Appointed	2025-03-25	2025-03-27

Key facts CIK 1761612 CUSIP 088786108 13F (30d) 48 filings 48 filers Visit website Investor relations